drugset / Trial / NCT04427475
Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
To detect the difference of PD-L1 and miRNA expression profiles of exosomes in NSCLC patients before and after immunotherapy, and to explore the potential of plasma exosomes PD-L1 and miRNAs as biomarkers to predict the therapeutic effect of NSCLC on anti-PD-1 / PD-L1.
Timeline
- Start
- 2020-06-08
- Primary completion
- 2021-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | nafulizumab | Unknown | — | — |
| Subject | pabolizumab | Unknown | — | — |